Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
This study involves being treated initially with a combination of drugs called irinotecan and
cisplatin (induction therapy), followed by treatment with a drug called Gleevec (maintenance
therapy). The main purpose of this study is to determine if this type of treatment will delay
the growth of the tumor and if so, for how long. The investigators also want to find out how
the tumor is affected solely by induction therapy with irinotecan and cisplatin, what
side-effects occur when Gleevec maintenance therapy is used, and if this treatment (induction
followed by maintenance therapy) will improve the duration of survival
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center